



European Medicines Agency
Evaluation of Medicines for Human Use

London, 22 October 2009
Doc.Ref.EMA/CHMP/681835/2009

**COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE
POST-AUTHORISATION SUMMARY OF POSITIVE OPINION***
for
KINZALMONO

International Nonproprietary Name (INN): *telmisartan*

On 22 October 2009 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion** to recommend the variation to the terms of the marketing authorisation for the medicinal product Kinzalmono. The Marketing Authorisation Holder for this medicinal product is Bayer Schering Pharma AG.

The CHMP adopted a new indication as follows:

“Cardiovascular prevention

Reduction of cardiovascular morbidity in patients with:

- i) manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or
- ii) type 2 diabetes mellitus with documented target organ damage”.

Detailed conditions for the use of this product will be described in the updated Summary of Product Characteristics (SPC) which will be published in the revised European Public Assessment Report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

* Summaries of positive opinion are published without prejudice to the Commission Decision, which will normally be issued within 44 days (Type II variations) and 67 days (Annex II applications) from adoption of the Opinion.

** Marketing Authorisation Holders may request a re-examination of any CHMP opinion, provided they notify the EMA in writing of their intention to request a re-examination within 15 days of receipt of the opinion.